New therapies for optic neuropathies

Development in experimental models

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Experimental models of human diseases have affected the design and direction of both basic and clinical research into understanding the pathogenesis and treatments of demyelinating disease, stroke, and hereditary disorders of the central nervous system. However, in spite of major advances in molecular research that have linked Leber Hereditary Optic Neuropathy to mutations in mitochondrial DNA, there has been relatively little focus in applying basic scientific methodologies to optic neuropathies other than glaucoma. The relative absence of detailed scientific knowledge about the basic mechanisms involved in the pathogenesis of optic nerve injury has contributed to the use of empiric therapies for neuro-ophthalmic optic neuropathies. Over the past decade major clinical trials, such as the Optic Neuritis Treatment Trial and Ischemic Optic Neuropathy Decompression Trial, have proven that currently available treatment options for demyelinating and ischemic optic neuropathies are ineffective and can even be harmful. Although the pathogenesis of visual failure in demyelinating, ischemic, and hereditary optic neuropathies appears diverse, a final common pathway for irreparable optic nerve injury may exist. This article reviews several models of experimental optic neuropathies that may aid in the development of novel treatments for neuro-ophthalmic disorders of the optic nerve during the 21st century. (C) 2000 Lippincoff Williams and Wilkins, Inc.

Original languageEnglish
Pages (from-to)421-429
Number of pages9
JournalCurrent Opinion in Ophthalmology
Volume11
Issue number6
DOIs
StatePublished - Dec 18 2000
Externally publishedYes

Fingerprint

Optic Nerve Diseases
Ischemic Optic Neuropathy
Theoretical Models
Optic Nerve Injuries
Leber's Hereditary Optic Atrophy
Therapeutics
Optic Neuritis
Central Nervous System Diseases
Demyelinating Diseases
Optic Nerve
Decompression
Mitochondrial DNA
Research
Glaucoma
Stroke
Clinical Trials
Mutation

ASJC Scopus subject areas

  • Ophthalmology

Cite this

New therapies for optic neuropathies : Development in experimental models. / Guy, John.

In: Current Opinion in Ophthalmology, Vol. 11, No. 6, 18.12.2000, p. 421-429.

Research output: Contribution to journalArticle

@article{83a72d51598e4d0fa0d3c4e491873713,
title = "New therapies for optic neuropathies: Development in experimental models",
abstract = "Experimental models of human diseases have affected the design and direction of both basic and clinical research into understanding the pathogenesis and treatments of demyelinating disease, stroke, and hereditary disorders of the central nervous system. However, in spite of major advances in molecular research that have linked Leber Hereditary Optic Neuropathy to mutations in mitochondrial DNA, there has been relatively little focus in applying basic scientific methodologies to optic neuropathies other than glaucoma. The relative absence of detailed scientific knowledge about the basic mechanisms involved in the pathogenesis of optic nerve injury has contributed to the use of empiric therapies for neuro-ophthalmic optic neuropathies. Over the past decade major clinical trials, such as the Optic Neuritis Treatment Trial and Ischemic Optic Neuropathy Decompression Trial, have proven that currently available treatment options for demyelinating and ischemic optic neuropathies are ineffective and can even be harmful. Although the pathogenesis of visual failure in demyelinating, ischemic, and hereditary optic neuropathies appears diverse, a final common pathway for irreparable optic nerve injury may exist. This article reviews several models of experimental optic neuropathies that may aid in the development of novel treatments for neuro-ophthalmic disorders of the optic nerve during the 21st century. (C) 2000 Lippincoff Williams and Wilkins, Inc.",
author = "John Guy",
year = "2000",
month = "12",
day = "18",
doi = "10.1097/00055735-200012000-00007",
language = "English",
volume = "11",
pages = "421--429",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - New therapies for optic neuropathies

T2 - Development in experimental models

AU - Guy, John

PY - 2000/12/18

Y1 - 2000/12/18

N2 - Experimental models of human diseases have affected the design and direction of both basic and clinical research into understanding the pathogenesis and treatments of demyelinating disease, stroke, and hereditary disorders of the central nervous system. However, in spite of major advances in molecular research that have linked Leber Hereditary Optic Neuropathy to mutations in mitochondrial DNA, there has been relatively little focus in applying basic scientific methodologies to optic neuropathies other than glaucoma. The relative absence of detailed scientific knowledge about the basic mechanisms involved in the pathogenesis of optic nerve injury has contributed to the use of empiric therapies for neuro-ophthalmic optic neuropathies. Over the past decade major clinical trials, such as the Optic Neuritis Treatment Trial and Ischemic Optic Neuropathy Decompression Trial, have proven that currently available treatment options for demyelinating and ischemic optic neuropathies are ineffective and can even be harmful. Although the pathogenesis of visual failure in demyelinating, ischemic, and hereditary optic neuropathies appears diverse, a final common pathway for irreparable optic nerve injury may exist. This article reviews several models of experimental optic neuropathies that may aid in the development of novel treatments for neuro-ophthalmic disorders of the optic nerve during the 21st century. (C) 2000 Lippincoff Williams and Wilkins, Inc.

AB - Experimental models of human diseases have affected the design and direction of both basic and clinical research into understanding the pathogenesis and treatments of demyelinating disease, stroke, and hereditary disorders of the central nervous system. However, in spite of major advances in molecular research that have linked Leber Hereditary Optic Neuropathy to mutations in mitochondrial DNA, there has been relatively little focus in applying basic scientific methodologies to optic neuropathies other than glaucoma. The relative absence of detailed scientific knowledge about the basic mechanisms involved in the pathogenesis of optic nerve injury has contributed to the use of empiric therapies for neuro-ophthalmic optic neuropathies. Over the past decade major clinical trials, such as the Optic Neuritis Treatment Trial and Ischemic Optic Neuropathy Decompression Trial, have proven that currently available treatment options for demyelinating and ischemic optic neuropathies are ineffective and can even be harmful. Although the pathogenesis of visual failure in demyelinating, ischemic, and hereditary optic neuropathies appears diverse, a final common pathway for irreparable optic nerve injury may exist. This article reviews several models of experimental optic neuropathies that may aid in the development of novel treatments for neuro-ophthalmic disorders of the optic nerve during the 21st century. (C) 2000 Lippincoff Williams and Wilkins, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033663422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033663422&partnerID=8YFLogxK

U2 - 10.1097/00055735-200012000-00007

DO - 10.1097/00055735-200012000-00007

M3 - Article

VL - 11

SP - 421

EP - 429

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 6

ER -